Shared and unique common genetic determinants between pediatric and adult celiac disease

Sabyasachi Senapati1,2, Ajit Sood3, Vandana Midha4

  • 1Department of Genetics, University of Delhi South Campus, New Delhi, 110021, India.

BMC Medical Genomics
|July 25, 2016
PubMed

Insights

Celiac disease (CD) in children and adults shares common genetic risk factors, suggesting they are part of the same disease spectrum. Further research is needed to explore novel genetic determinants and clinical heterogeneity.

Area of Science:

  • Genetics and immunology
  • Gastroenterology
  • Pediatric and adult medicine

Background:

  • Celiac disease (CD) is classified by age of onset: pediatric CD and adult CD.
  • The genetic and phenotypic distinctions between pediatric and adult CD remain unclear.
  • This study investigates shared genetic components in pediatric and adult CD within a North Indian cohort.

Purpose of the Study:

  • To determine if pediatric and adult celiac disease are genetically and phenotypically distinct or represent a spectrum of the same condition.
  • To explore common genetic underpinnings of celiac disease across different age groups.
  • To identify shared and novel genetic risk determinants in pediatric and adult celiac disease.

Main Methods:

  • Retrospective analysis of 531 pediatric and 871 adult CD patients (2001-2010).
  • Genotyping using Immunochip for 217 pediatric CD, 340 adult CD patients, and 736 controls.
  • Association analysis via logistic regression to identify susceptibility genetic variants.

Main Results:

  • Classical CD was predominant in both pediatric and adult groups.
  • Similarities were observed, with quantitative differences in female preponderance, presentation type, and autoimmune comorbidities.
  • Shared HLA-DQ2 and -DQ8 haplotypes were major risk factors; ANK3 (rs4948256-A; rs10994257-T) was a suggestively associated non-HLA marker.

Conclusions:

  • Pediatric and adult CD appear to be part of the same disease spectrum, supported by shared HLA risk alleles.
  • Non-HLA genes may influence disease onset and extra-intestinal manifestations, requiring further functional investigation.
  • This study provides the first comparative genetic analysis suggesting shared and novel risk determinants for CD across age groups.
Abstract

Related Concept Videos

Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
32.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Pedigree Analysis01:35

Pedigree Analysis

Overview
90.5K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
73